Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699).

Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment

“…Despite the promising impact observed in the context of retrospective analyses, further prospective evaluations failed to demonstrate the predictive applicability of these factors. [33][34][35][36][37] A recent retrospective immunohistochemistry analysis suggested that the concomitant overexpression of b-catenin and cyclin D1 might be associated with poor survival regardless of platinumbased adjuvant chemotherapy in stage IA or IIA SQLC. 38 All things considered, to date, no factors (other than histological subtype in the advanced setting) have been demonstrated to be predictive of benefit or lack of benefit from specific chemotherapeutic agents in patients with NSCLC.…”

Scientific Advances in Lung Cancer 2015

“…126 A recent study that randomized patients to receive customized chemotherapy on the basis of breast cancer 1 expression levels (BRACA1) failed to meet its primary end point. 127 Another study by the French Intergroup that evaluated customization of chemotherapy based on excision repair crosscomplementation group 1 (ERCC1) was discontinued on account of unreliability of the ERCC1 assay. 128 The results of an Italian study (ITACA) that addresses customized chemotherapy based on thymidylate synthase and ERCC1 levels in the tumor are eagerly awaited.…”

Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Carcinoma

“…is another protein involved in DNA repair. Despite encouraging preliminary data on its impact on chemoresistance prediction in advanced-stage NSCLC [17,18], a recent phase III trial testing customized chemotherapy according to BRCA1 level was reported as negative [19]. There is therefore an urgent need to validate new predictive markers.…”